BIOXYTRAN, INC
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-30; filed 2025-08-11.
0001493152-25-011797
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2025-09-30; filed 2025-11-14.
0001493152-25-023399
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 32 previous paragraphs and 34 current paragraphs.
26 unchanged; 5 reworded; 3 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 24 previous and 24 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (3)
Current report
OPERATING EXPENSES
Current report
LIQUIDITY AND CAPITAL RESOURCES
Removed paragraphs (1)
Previous report
Non-Controlling Interest
Reworded paragraphs (5)
Previous wording
Bioxytran, Inc. is headquartered in Needham, Massachusetts. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis drug specifically designed to treat a person immediately after that person suffers an ischemic stroke. The drug is designed to be injected intravenously to travel to the lungs to pick up oxygen molecules to carry to the brain. Like a red blood cell, the drug will cross the blood brain barrier, which is a protective semi-permeable membrane allowing some material to cross but preventing others from crossing. BXT-25 will be designed to diffuse oxygen into the brain tissues. We expect the BXT-25 molecule to be 5,000 times smaller than a red blood cell.
Current wording
Bioxytran, Inc. is headquartered in Needham, Massachusetts. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis drug specifically designed to treat a person immediately after that person suffers an ischemic stroke. The drug is designed to be injected intravenously to travel to the lungs to pick up oxygen molecules to carry to the brain. Like a red blood cell, the drug will cross the blood brain barrier, which is a protective semi-permeable membrane allowing some material to cross but preventing others from crossing. BXT-25 will be designed to diffuse oxygen into the brain tissues. We expect the BXT-25 molecule to be 1,000 times smaller than a red blood cell.
Previous wording
Provided that the Company obtain adequate funding, the following future milestones are anticipated:
Current wording
Provided that the Company obtains adequate funding, the following future milestones are anticipated:
Previous wording
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. The Company currently has one convertible loan outstanding at a total face value of $805,000 with an accrued interest of $204,911 and a linked derivative debt of $684,002. The remaining debt mounts to $1,066,136 (whereof $502,255 is owed to affiliates with an accrued interest of $22,948). As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $20,239,366 as at June 30, 2025. The accumulated deficit as at December 31, 2024, was $18,921,169.
Current wording
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. As at September 30, 2025, the Company has one convertible loan outstanding at a total face value of $805,000 with an accrued interest of $241,433 and a estimated derivative debt of $419,206. The remaining debt mounts to $1,595,517 (whereof $541,405 is owed to affiliates with an accrued interest of $33,707). As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $20,522,092 as at September 30, 2025. The accumulated deficit as at December 31, 2024, was $18,921,169.
Previous wording
RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025, AND 2024
Current wording
RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
Previous wording
Despite the ongoing promotional activities, the Company still struggle with a deflated stock price on OTC Markets which makes it very difficult to raise funds without heavily discounting the price and diluting the shareholders. The Company is actively working on finding financing alternatives in order to continue its regulatory approval activities and intends to issue a Private Placement Offering under Regulation D in the order of $2 million in the spring of 2025.
Current wording
Despite the ongoing promotional activities, the Company still struggle with a deflated stock price on OTC Markets which makes it very difficult to raise funds without heavily discounting the price and diluting the shareholders. On November 14, 2025, the Company closed a Private Placement Offering under Regulation D of $430,000 for 8,600,000 units at a price of $0.05 per unit. Each unit consisted of one (1) share of Common Stock and one (1) warrant share exercisable at $0.12 per share. The shares were offered through a broker (Member FINRA / SIPC) against a fee, of (i) 8.0% of the gross proceeds in cash, and (ii) 8.0% of units sold in shares of Common Stock.